Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
- 1 April 2021
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (4), 1027-1037
- https://doi.org/10.2337/dc20-1843
Abstract
OBJECTIVE Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a major apolipoprotein. This prompted us to study the effect of the GLP-1 agonist liraglutide on the metabolism of apoB100-containing lipoproteins. RESEARCH DESIGN AND METHODS We performed an in vivo kinetic study with stable isotopes (L-[1-C-13]leucine) in 10 patients with T2D before and after 6 months of treatment with liraglutide (1.2 mg/day). We also evaluated in mice the effect of liraglutide on the expression of genes involved in apoB100-containing lipoprotein clearance. RESULTS In patients with T2D, liraglutide treatment significantly reduced plasma apoB100 (0.93 +/- 0.13 vs. 1.09 +/- 0.11 g/L, P = 0.011) and fasting triglycerides (1.76 +/- 0.37 vs. 2.48 +/- 0.69 mmol/L, P = 0.005). The kinetic study showed a significant increase in indirect catabolism of VLDL1-apoB100 (4.11 +/- 1.91 vs. 2.96 +/- 1.61 pools/day, P = 0.005), VLDL2-apoB100 (5.17 +/- 2.53 vs. 2.84 +/- 1.65 pools/day, P = 0.008), and IDL-apoB100 (5.27 +/- 2.77 vs. 3.74 +/- 1.85 pools/day, P = 0.017) and in catabolism of LDL-apoB100 (0.72 +/- 0.22 vs. 0.56 +/- 0.22 pools/day, P = 0.005). In mice, liraglutide increased lipoprotein lipase (LPL) gene expression and reduced proprotein convertase subtilisin/kexin type 9 (PCSK9), retinol-binding protein 4 (RBP4), and tumor necrosis factor-alpha (TNF-alpha) gene expression in adipose tissue and decreased PCSK9 mRNA and increased LDL receptor protein expression in liver. In vitro, liraglutide directly reduced the expression of PCSK9 in the liver. CONCLUSIONS Treatment with liraglutide induces a significant acceleration of the catabolism of triglyceride-rich lipoproteins (VLDL1, VLDL2, IDL) and LDL. Liraglutide modifies the expression of genes involved in apoB100-containing lipoprotein catabolism. These positive effects on lipoprotein metabolism may reduce cardiovascular risk in T2D.Funding Information
- Novo Nordisk
- Agence Nationale de la Recherche (ANR-11-LABX-0021)
This publication has 64 references indexed in Scilit:
- Impact of Serum Retinol-Binding Protein 4 Levels on Regulation of Remnant-Like Particles Triglyceride in Type 2 Diabetes MellitusJournal of Diabetes Research, 2013
- GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden MicePLOS ONE, 2012
- Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular DiseaseJournal of the American Society of Nephrology, 2011
- Comparison of Different Measures of Urinary Protein Excretion for Prediction of Renal EventsJournal of the American Society of Nephrology, 2010
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathwayHepatology, 2010
- Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysisCanadian Journal of Diabetes, 2009
- Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipidsDiabetic Medicine, 2009
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)Diabetes Care, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Inflammation stimulates the expression of PCSK9Biochemical and Biophysical Research Communications, 2008